Vesalio Receives FDA 510(k) Clearance of enVast, the First Stent-Based Coronary Thrombectomy Technology
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform.
Vesalio Receives Two FDA 510(k) Clearances, Advancing Its Comprehensive Thrombectomy Platform with Aspiration Technology
The FDA clearances expand Vesalio’s thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion-dollar global thrombectomy market.
Vesalio Announces Launch of pVasc Study in the U.S. While Featuring the pVasc Thrombectomy System at VIVA, VEITH, and TCT
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
Vesalio launches pVasc Thrombectomy System in the U.S. for peripheral occlusions
Introducing pVasc™ mechanical thrombectomy system for the safe and effective non-surgical removal of occlusions from the peripheral vasculature
VESALIO Introduces NeVa NET 4.0 mm Following International Success of NeVa NET 5.5 mm
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology.
Vesalio appoints CFO and announces company headquarters in Dallas, Texas
Introducing pVasc™ mechanical thrombectomy system for the safe and effective non-surgical removal of occlusions from the peripheral vasculature
NeVa CLEAR Study results presented at ESMINT: innovative thrombectomy device achieves notable first-pass success and patient outcomes
Primary results from the CLEAR Study were presented at the ESMINT annual meeting in Marseille, France (4-6 September 2023), where Vesalio also announced the fifth anniversary of the international commercialization of the NeVa™ device.
Vesalio Announces Initial Use of its Uniquely Designed and FDA-approved NeVa VS Device
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
Vesalio appoints VP of U.S. Sales and announces recent publication on NeVa showing impressive first pass rates
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology.
Vesalio announces EU MDR Certification
MDR certification confirms the company’s commitment of ensuring that their innovative new products meet or exceed these rigorous new standards.
